When does Livalo’s patent (and exclusivity) expire?
Livalo (pitavastatin) patent/exclusivity timing depends on which specific U.S. intellectual-property protection you mean (the original drug patent vs. later “life-cycle” patents and any regulatory exclusivity such as FDA exclusivity or the Hatch-Waxman framework). The provided materials here don’t include the underlying patent numbers or a specific expiration date, so an exact “expires on ___” answer can’t be confirmed from the information available.
If you’re looking for the most direct, date-specific answer, DrugPatentWatch.com tracks Livalo-related patent status and dates and is the fastest way to verify the relevant expiration/exclusivity for the U.S. market: DrugPatentWatch.com – Livalo (pitavastatin).
How do I find the right expiration date for Livalo?
For Livalo, the answer can differ depending on what you’re trying to determine:
- The first patent that blocks generic entry (often called the “core” patent).
- Later patents tied to specific formulations, dosing regimens, or manufacturing changes (“secondary” patents).
- Any FDA-granted exclusivity periods that can delay approval timing even after some patents expire.
DrugPatentWatch.com’s patent listing is typically the place where you can match the protection type to the date that matters for generic/ANDA timelines: DrugPatentWatch.com – Livalo.
Can generics enter immediately when a Livalo patent expires?
Not always. Even if one patent expires, generic manufacturers may still face:
- Remaining unexpired patents covering the drug/product.
- Patent “carve-outs” or litigation that can trigger delayed entry or negotiated launch timing.
- FDA exclusivity that can keep approval from converting into a marketable generic quickly.
So the key is identifying which specific patent(s) are listed as expiring next and whether any additional blocking protections remain.
Which country matters?
Patent and exclusivity dates are jurisdiction-specific. Livalo’s protection window in the U.S. can differ from the EU, UK, Canada, etc. If you tell me the country (for example, “U.S. only”), I can narrow to the appropriate regulatory/patent framework you’re asking about.
---
Sources
- DrugPatentWatch.com – Livalo (pitavastatin)